A PROSPECTIVE OBSERVATIONAL STUDY OF ROLE AND MANAGEMENT OF STATINS IN CORONARY ARTERY DISEASE

Abstract Introduction: statins therapies are a cornerstone in the management of coronary artery disease (CAD), largely due to the prominent role of lipids and triglycerides play in the pathophysiology of the disease. HMG-CoA enzyme inhibitors are integral to the management of CAD Aim: the study aims to evaluate the real-world efficacy, adverse effect, symptoms, co-morbidities, and lipid profile of HMG-CoA enzyme inhibitors in CAD management. Methods: a meticulously designed prospective observational study was conducted on patients diagnosed with CAD, including acute coronary syndrome (ACS), Anterior Wall Myocardial Infarction (AWMI), unstable angina, myocardial infraction (MI). participants were stratified based on the prescribed HMG-CoA enzyme inhibitors. Key clinical endpoints, such as side effects, adverse effect, symptoms, co-morbidities, lipid profile and all-cause mortality were assessed over a structured 1-month follow-up period. Result: A total of 100 patients were enrolled. After 1 month of taking HMG-CoA enzyme inhibitors side effects, with muscle pain, weakness, headache, stomach pain the majority of recurring symptoms were observed in patients aged 41-80 years. The risk-benefit equilibrium of these agents underscores the necessity of precision medicine in tailoring statins therapy for CAD patients. Conclusion: HMG-CoA enzyme inhibitors integral to contemporary CAD management, with Atorvastatin and Rosuvastatin being most commonly used drugs in this disease. In this study, the adverse effects of statins are mild and transient. Fewer patients experienced sleeplessness after using these drugs, and overall, symptoms and side effects were relatively manageable. However, a significant portion of patients experienced side effects after taking HMG-CoA enzyme inhibitors in the management of coronary artery disease